| |
KLSE: AHEALTH (7090) | APEX HEALTHCARE BHD | MAIN : Health Care |
Last Price | Today's Change | Day's Range | Trading Volume |
3.55 | 0.00 (0.00%) | 3.48 - 3.56 | 57,000 |
Trade this stock with 3 x trading limit. Find out more. |
Financials
Market Cap: 1,687 Million
| Latest Audited Result: 31-Dec-2019
| Latest Quarter: 30-Sep-2020 [#3]
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Annual (Unaudited) ( EPS: 11.10, P/E: 31.98 )
| T4Q Result ( EPS: 11.71, P/E: 30.33 )
| Annualized Result ( EPS: 11.68, P/E: 30.40 )
|
Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.
Click here to modify the Visible Columns.
Date | Financial Result | Financial Ratio | Per Share Item | Performance | Valuation (End of Quarter) | Valuation (Ann. Date) | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
F.Y. | Ann. Date | Quarter | # | Revenue | PBT | NP | NP to SH | Div | Net Worth | Div Payout % | NP Margin | ROE | NOSH | RPS | Adj. RPS | EPS | Adj. EPS | DPS | Adj. DPS | NAPS | Adj. NAPS | QoQ | YoY | EOQ Date | EOQ Price | EOQ P/RPS | EOQ P/EPS | EOQ P/NAPS | EOQ EY | EOQ DY | ANN Date | ANN Price | ANN P/RPS | ANN P/EPS | ANN P/NAPS | ANN EY | ANN DY |
31-Dec-2020 | 19-Nov-2020 | 30-Sep-2020 | 3 | 537,152 | 51,773 | 41,638 | 41,627 | 8,041 | 454,102 | 19.32% | 7.75% | 9.17% | 473,023 | 113.56 | 113.03 | 8.80 | 8.76 | 1.70 | 1.69 | 0.9600 | 0.96 | ![]() | ![]() | 30-Sep-2020 | 3.24 | 2.85 | 36.82 | 3.38 | 2.72% | 0.52% | 19-Nov-2020 | 3.60 | 3.17 | 40.91 | 3.75 | 2.44% | 0.47% |
31-Dec-2020 | 26-Aug-2020 | 30-Jun-2020 | 2 | 368,036 | 34,285 | 27,292 | 27,404 | 8,032 | 444,145 | 29.31% | 7.42% | 6.17% | 472,495 | 77.89 | 77.44 | 5.80 | 5.77 | 1.70 | 1.69 | 0.9400 | 0.93 | ![]() | ![]() | 30-Jun-2020 | 2.80 | 3.59 | 48.28 | 2.98 | 2.07% | 0.61% | 26-Aug-2020 | 3.72 | 4.78 | 64.14 | 3.96 | 1.56% | 0.46% |
31-Dec-2020 | 21-May-2020 | 31-Mar-2020 | 1 | 193,308 | 17,944 | 14,362 | 14,370 | - | 438,661 | - % | 7.43% | 3.28% | 471,679 | 40.98 | 40.68 | 3.05 | 3.02 | 0.00 | 0.00 | 0.9300 | 0.92 | ![]() | ![]() | 31-Mar-2020 | 2.11 | 5.15 | 69.26 | 2.27 | 1.44% | 0.00% | 21-May-2020 | 2.90 | 7.08 | 95.19 | 3.12 | 1.05% | 0.00% |
31-Dec-2019 | 19-Feb-2020 | 31-Dec-2019 | 4 | 688,786 | 66,334 | 52,772 | 52,750 | 17,438 | 424,170 | 33.06% | 7.66% | 12.44% | 471,301 | 146.15 | 144.94 | 11.19 | 11.10 | 3.70 | 3.67 | 0.9000 | 0.89 | ![]() | ![]() | 31-Dec-2019 | 2.24 | 1.53 | 20.01 | 2.49 | 5.00% | 1.65% | 19-Feb-2020 | 2.41 | 1.65 | 21.53 | 2.68 | 4.64% | 1.54% |
31-Dec-2019 | 21-Nov-2019 | 30-Sep-2019 | 3 | 518,152 | 47,850 | 38,766 | 38,746 | 8,011 | 409,992 | 20.68% | 7.48% | 9.45% | 471,256 | 109.95 | 109.03 | 8.22 | 8.15 | 1.70 | 1.69 | 0.8700 | 0.86 | ![]() | ![]() | 30-Sep-2019 | 2.18 | 1.98 | 26.51 | 2.51 | 3.77% | 0.78% | 21-Nov-2019 | 2.40 | 2.18 | 29.19 | 2.76 | 3.43% | 0.71% |
31-Dec-2019 | 21-Aug-2019 | 30-Jun-2019 | 2 | 337,499 | 30,726 | 24,644 | 24,623 | 8,008 | 405,125 | 32.52% | 7.30% | 6.08% | 471,076 | 71.64 | 71.02 | 5.23 | 5.18 | 1.70 | 1.69 | 0.8600 | 0.85 | ![]() | ![]() | 28-Jun-2019 | 2.17 | 3.03 | 41.52 | 2.52 | 2.41% | 0.78% | 21-Aug-2019 | 2.03 | 2.83 | 38.84 | 2.36 | 2.57% | 0.84% |
31-Dec-2019 | 23-May-2019 | 31-Mar-2019 | 1 | 178,229 | 14,543 | 11,414 | 11,399 | - | 392,099 | - % | 6.40% | 2.91% | 117,395 | 151.82 | 37.50 | 9.71 | 2.40 | 0.00 | 0.00 | 3.3400 | 0.83 | ![]() | ![]() | 29-Mar-2019 | 8.87 | 5.84 | 91.35 | 2.66 | 1.09% | 0.00% | 23-May-2019 | 8.60 | 5.66 | 88.57 | 2.57 | 1.13% | 0.00% |
31-Dec-2018 | 28-Feb-2019 | 31-Dec-2018 | 4 | 652,660 | 69,270 | 58,667 | 58,581 | 15,834 | 381,202 | 27.03% | 8.99% | 15.37% | 117,293 | 556.44 | 137.34 | 49.94 | 12.33 | 13.50 | 3.33 | 3.2500 | 0.80 | ![]() | ![]() | 31-Dec-2018 | 7.80 | 1.40 | 15.62 | 2.40 | 6.40% | 1.73% | 28-Feb-2019 | 8.95 | 1.61 | 17.92 | 2.75 | 5.58% | 1.51% |
31-Dec-2018 | 15-Nov-2018 | 30-Sep-2018 | 3 | 489,599 | 52,531 | 41,864 | 41,777 | 7,616 | 365,595 | 18.23% | 8.55% | 11.43% | 117,178 | 417.83 | 103.02 | 35.65 | 8.79 | 6.50 | 1.60 | 3.1200 | 0.77 | ![]() | ![]() | 28-Sep-2018 | 8.25 | 1.97 | 23.14 | 2.64 | 4.32% | 0.79% | 15-Nov-2018 | 8.10 | 1.94 | 22.72 | 2.60 | 4.40% | 0.80% |
31-Dec-2018 | 16-Aug-2018 | 30-Jun-2018 | 2 | 324,346 | 33,894 | 26,922 | 26,880 | 7,614 | 360,809 | 28.33% | 8.30% | 7.45% | 117,146 | 276.87 | 68.25 | 22.95 | 5.66 | 6.50 | 1.60 | 3.0800 | 0.76 | ![]() | ![]() | 29-Jun-2018 | 6.79 | 2.45 | 29.59 | 2.20 | 3.38% | 0.96% | 16-Aug-2018 | 7.25 | 2.62 | 31.60 | 2.35 | 3.16% | 0.90% |
31-Dec-2018 | 24-May-2018 | 31-Mar-2018 | 1 | 168,400 | 16,526 | 13,221 | 13,181 | - | 356,123 | - % | 7.85% | 3.70% | 117,146 | 143.75 | 35.44 | 11.25 | 2.77 | 0.00 | 0.00 | 3.0400 | 0.75 | ![]() | ![]() | 30-Mar-2018 | 5.48 | 3.81 | 48.70 | 1.80 | 2.05% | 0.00% | 24-May-2018 | 5.76 | 4.01 | 51.19 | 1.89 | 1.95% | 0.00% |
31-Dec-2017 | 22-Feb-2018 | 31-Dec-2017 | 4 | 620,264 | 56,047 | 44,488 | 44,459 | 14,057 | 343,237 | 31.62% | 7.17% | 12.95% | 117,146 | 529.48 | 130.52 | 37.95 | 9.36 | 12.00 | 2.96 | 2.9300 | 0.72 | ![]() | ![]() | 29-Dec-2017 | 5.60 | 1.06 | 14.76 | 1.91 | 6.78% | 2.14% | 22-Feb-2018 | 4.90 | 0.93 | 12.91 | 1.67 | 7.75% | 2.45% |
31-Dec-2017 | 14-Nov-2017 | 30-Sep-2017 | 3 | 467,679 | 39,667 | 31,689 | 31,658 | 6,443 | 330,351 | 20.35% | 6.78% | 9.58% | 117,146 | 399.23 | 98.41 | 27.02 | 6.66 | 5.50 | 1.36 | 2.8200 | 0.70 | ![]() | ![]() | 29-Sep-2017 | 5.10 | 1.28 | 18.87 | 1.81 | 5.30% | 1.08% | 14-Nov-2017 | 5.50 | 1.38 | 20.35 | 1.95 | 4.91% | 1.00% |
31-Dec-2017 | 16-Aug-2017 | 30-Jun-2017 | 2 | 309,949 | 26,365 | 20,399 | 20,388 | 6,443 | 325,665 | 31.60% | 6.58% | 6.26% | 117,146 | 264.58 | 65.22 | 17.40 | 4.29 | 5.50 | 1.36 | 2.7800 | 0.69 | ![]() | ![]() | 30-Jun-2017 | 4.70 | 1.78 | 27.01 | 1.69 | 3.70% | 1.17% | 16-Aug-2017 | 4.74 | 1.79 | 27.24 | 1.71 | 3.67% | 1.16% |
31-Dec-2017 | 17-May-2017 | 31-Mar-2017 | 1 | 154,652 | 12,912 | 10,099 | 10,091 | - | 322,151 | - % | 6.53% | 3.13% | 117,146 | 132.02 | 32.54 | 8.61 | 2.12 | 0.00 | 0.00 | 2.7500 | 0.68 | ![]() | ![]() | 31-Mar-2017 | 4.90 | 3.71 | 56.88 | 1.78 | 1.76% | 0.00% | 17-May-2017 | 4.70 | 3.56 | 54.56 | 1.71 | 1.83% | 0.00% |
31-Dec-2016 | 23-Feb-2017 | 31-Dec-2016 | 4 | 581,269 | 46,294 | 34,988 | 34,954 | 13,471 | 311,608 | 38.54% | 6.02% | 11.22% | 117,146 | 496.19 | 122.31 | 29.84 | 7.36 | 11.50 | 2.83 | 2.6600 | 0.66 | ![]() | ![]() | 30-Dec-2016 | 4.30 | 0.87 | 14.41 | 1.62 | 6.94% | 2.67% | 23-Feb-2017 | 4.65 | 0.94 | 15.58 | 1.75 | 6.42% | 2.47% |
31-Dec-2016 | 15-Nov-2016 | 30-Sep-2016 | 3 | 437,123 | 36,215 | 28,222 | 28,198 | - | 301,065 | - % | 6.46% | 9.37% | 117,146 | 373.14 | 91.98 | 24.07 | 5.93 | 0.00 | 0.00 | 2.5700 | 0.63 | ![]() | ![]() | 30-Sep-2016 | 4.54 | 1.22 | 18.86 | 1.77 | 5.30% | 0.00% | 15-Nov-2016 | 4.60 | 1.23 | 19.11 | 1.79 | 5.23% | 0.00% |
31-Dec-2016 | 17-Aug-2016 | 30-Jun-2016 | 2 | 294,163 | 24,679 | 19,474 | 19,462 | 6,443 | 298,722 | 33.11% | 6.62% | 6.52% | 117,146 | 251.11 | 61.90 | 16.61 | 4.10 | 5.50 | 1.36 | 2.5500 | 0.63 | ![]() | ![]() | 30-Jun-2016 | 3.89 | 1.55 | 23.41 | 1.53 | 4.27% | 1.41% | 17-Aug-2016 | 3.82 | 1.52 | 22.99 | 1.50 | 4.35% | 1.44% |
31-Dec-2016 | 18-May-2016 | 31-Mar-2016 | 1 | 147,478 | 12,366 | 9,819 | 9,813 | - | 296,379 | - % | 6.66% | 3.31% | 117,146 | 125.89 | 31.03 | 8.38 | 2.06 | 0.00 | 0.00 | 2.5300 | 0.62 | ![]() | ![]() | 31-Mar-2016 | 3.73 | 2.96 | 44.53 | 1.47 | 2.25% | 0.00% | 18-May-2016 | 3.94 | 3.13 | 47.04 | 1.56 | 2.13% | 0.00% |
31-Dec-2015 | 25-Feb-2016 | 31-Dec-2015 | 4 | 526,859 | 45,842 | 34,263 | 34,236 | 12,886 | 288,179 | 37.64% | 6.50% | 11.88% | 117,146 | 449.75 | 110.86 | 29.23 | 7.20 | 11.00 | 2.71 | 2.4600 | 0.61 | ![]() | ![]() | 31-Dec-2015 | 3.60 | 0.80 | 12.32 | 1.46 | 8.12% | 3.06% | 25-Feb-2016 | 3.41 | 0.76 | 11.67 | 1.39 | 8.57% | 3.23% |
31-Dec-2015 | 26-Nov-2015 | 30-Sep-2015 | 3 | 392,611 | 28,677 | 20,436 | 20,430 | - | 274,121 | - % | 5.21% | 7.45% | 117,146 | 335.15 | 82.62 | 17.44 | 4.30 | 0.00 | 0.00 | 2.3400 | 0.58 | ![]() | ![]() | 30-Sep-2015 | 3.95 | 1.18 | 22.65 | 1.69 | 4.42% | 0.00% | 26-Nov-2015 | 3.70 | 1.10 | 21.22 | 1.58 | 4.71% | 0.00% |
31-Dec-2015 | 19-Aug-2015 | 30-Jun-2015 | 2 | 264,343 | 20,956 | 15,048 | 15,049 | 5,857 | 268,264 | 38.92% | 5.69% | 5.61% | 117,146 | 225.65 | 55.62 | 12.85 | 3.17 | 5.00 | 1.23 | 2.2900 | 0.56 | ![]() | ![]() | 30-Jun-2015 | 4.02 | 1.78 | 31.29 | 1.76 | 3.20% | 1.24% | 19-Aug-2015 | 3.95 | 1.75 | 30.75 | 1.72 | 3.25% | 1.27% |
31-Dec-2015 | 20-May-2015 | 31-Mar-2015 | 1 | 140,064 | 11,880 | 8,446 | 8,446 | - | 268,264 | - % | 6.03% | 3.15% | 117,146 | 119.56 | 29.47 | 7.21 | 1.78 | 0.00 | 0.00 | 2.2900 | 0.56 | ![]() | ![]() | 31-Mar-2015 | 3.90 | 3.26 | 54.09 | 1.70 | 1.85% | 0.00% | 20-May-2015 | 3.95 | 3.30 | 54.79 | 1.72 | 1.83% | 0.00% |
31-Dec-2014 | 25-Feb-2015 | 31-Dec-2014 | 4 | 499,237 | 45,624 | 33,977 | 33,977 | 11,128 | 260,064 | 32.75% | 6.81% | 13.06% | 117,146 | 426.17 | 105.05 | 28.91 | 7.15 | 9.50 | 2.34 | 2.2200 | 0.55 | ![]() | ![]() | 31-Dec-2014 | 3.58 | 0.84 | 12.34 | 1.61 | 8.10% | 2.65% | 25-Feb-2015 | 3.64 | 0.85 | 12.55 | 1.64 | 7.97% | 2.61% |
31-Dec-2014 | 18-Nov-2014 | 30-Sep-2014 | 3 | 375,932 | 32,953 | 24,432 | 24,432 | 4,100 | 249,520 | 16.78% | 6.50% | 9.79% | 117,146 | 320.91 | 79.11 | 20.78 | 5.14 | 3.50 | 0.86 | 2.1300 | 0.53 | ![]() | ![]() | 30-Sep-2014 | 3.86 | 1.20 | 18.51 | 1.81 | 5.40% | 0.91% | 18-Nov-2014 | 3.70 | 1.15 | 17.74 | 1.74 | 5.64% | 0.95% |
31-Dec-2014 | 20-Aug-2014 | 30-Jun-2014 | 2 | 253,420 | 22,672 | 17,022 | 17,022 | 4,100 | 246,006 | 24.09% | 6.72% | 6.92% | 117,146 | 216.33 | 53.33 | 14.48 | 3.58 | 3.50 | 0.86 | 2.1000 | 0.52 | ![]() | ![]() | 30-Jun-2014 | 3.80 | 1.76 | 26.15 | 1.81 | 3.82% | 0.92% | 20-Aug-2014 | 3.85 | 1.78 | 26.50 | 1.83 | 3.77% | 0.91% |
31-Dec-2014 | 21-May-2014 | 31-Mar-2014 | 1 | 130,927 | 12,622 | 9,468 | 9,468 | - | 244,601 | - % | 7.23% | 3.87% | 93,717 | 139.70 | 27.55 | 10.07 | 1.99 | 0.00 | 0.00 | 2.6100 | 0.51 | ![]() | ![]() | 31-Mar-2014 | 4.60 | 3.29 | 45.53 | 1.76 | 2.20% | 0.00% | 21-May-2014 | 4.80 | 3.44 | 47.51 | 1.84 | 2.10% | 0.00% |
31-Dec-2013 | 26-Feb-2014 | 31-Dec-2013 | 4 | 418,451 | 40,615 | 30,122 | 30,123 | 9,373 | 235,264 | 31.12% | 7.20% | 12.80% | 93,730 | 446.44 | 88.05 | 25.63 | 6.34 | 10.00 | 1.97 | 2.5100 | 0.50 | ![]() | ![]() | 31-Dec-2013 | 4.50 | 1.01 | 14.00 | 1.79 | 7.14% | 2.22% | 26-Feb-2014 | 4.40 | 0.99 | 13.69 | 1.75 | 7.30% | 2.27% |
31-Dec-2013 | 20-Nov-2013 | 30-Sep-2013 | 3 | 312,241 | 30,049 | 22,479 | 22,405 | 3,748 | 224,893 | 16.73% | 7.20% | 9.96% | 93,705 | 333.22 | 65.70 | 23.91 | 4.71 | 4.00 | 0.79 | 2.4000 | 0.47 | ![]() | ![]() | 30-Sep-2013 | 4.80 | 1.44 | 20.08 | 2.00 | 4.98% | 0.83% | 20-Nov-2013 | 4.79 | 1.44 | 20.03 | 2.00 | 4.99% | 0.84% |
31-Dec-2013 | 21-Aug-2013 | 30-Jun-2013 | 2 | 210,561 | 21,470 | 15,967 | 15,925 | 3,749 | 223,081 | 23.54% | 7.58% | 7.14% | 93,731 | 224.64 | 44.31 | 16.99 | 3.35 | 4.00 | 0.79 | 2.3800 | 0.47 | ![]() | ![]() | 28-Jun-2013 | 4.49 | 2.00 | 26.43 | 1.89 | 3.78% | 0.89% | 21-Aug-2013 | 4.95 | 2.20 | 29.13 | 2.08 | 3.43% | 0.81% |
31-Dec-2013 | 22-May-2013 | 31-Mar-2013 | 1 | 106,359 | 12,197 | 9,134 | 9,113 | - | 225,949 | - % | 8.59% | 4.03% | 93,755 | 113.44 | 22.38 | 9.72 | 1.92 | 0.00 | 0.00 | 2.4100 | 0.48 | ![]() | ![]() | 29-Mar-2013 | 4.27 | 3.76 | 43.93 | 1.77 | 2.28% | 0.00% | 22-May-2013 | 4.37 | 3.85 | 44.96 | 1.81 | 2.22% | 0.00% |
31-Dec-2012 | 27-Feb-2013 | 31-Dec-2012 | 4 | 398,604 | 42,349 | 29,066 | 29,012 | 15,932 | 216,495 | 54.92% | 7.29% | 13.40% | 93,720 | 425.31 | 83.88 | 30.96 | 6.10 | 17.00 | 3.35 | 2.3100 | 0.46 | ![]() | ![]() | 31-Dec-2012 | 3.68 | 0.87 | 11.89 | 1.59 | 8.41% | 4.62% | 27-Feb-2013 | 4.14 | 0.97 | 13.37 | 1.79 | 7.48% | 4.11% |
31-Dec-2012 | 21-Nov-2012 | 30-Sep-2012 | 3 | 302,611 | 32,431 | 21,168 | 21,122 | 5,622 | 208,033 | 26.62% | 7.00% | 10.15% | 93,708 | 322.93 | 63.68 | 22.54 | 4.44 | 6.00 | 1.18 | 2.2200 | 0.44 | ![]() | ![]() | 28-Sep-2012 | 3.28 | 1.02 | 14.55 | 1.48 | 6.87% | 1.83% | 21-Nov-2012 | 3.56 | 1.10 | 15.79 | 1.60 | 6.33% | 1.69% |
31-Dec-2012 | 15-Aug-2012 | 30-Jun-2012 | 2 | 204,804 | 23,660 | 14,711 | 14,682 | 5,621 | 206,128 | 38.29% | 7.18% | 7.12% | 93,694 | 218.59 | 43.10 | 15.67 | 3.09 | 6.00 | 1.18 | 2.2000 | 0.43 | ![]() | ![]() | 29-Jun-2012 | 2.95 | 1.35 | 18.83 | 1.34 | 5.31% | 2.03% | 15-Aug-2012 | 3.11 | 1.42 | 19.85 | 1.41 | 5.04% | 1.93% |
31-Dec-2012 | 23-May-2012 | 31-Mar-2012 | 1 | 104,126 | 12,327 | 6,337 | 6,320 | - | 205,353 | - % | 6.09% | 3.08% | 93,768 | 111.05 | 21.91 | 6.74 | 1.33 | 0.00 | 0.00 | 2.1900 | 0.43 | ![]() | ![]() | 30-Mar-2012 | 2.94 | 2.65 | 43.62 | 1.34 | 2.29% | 0.00% | 23-May-2012 | 2.78 | 2.50 | 41.25 | 1.27 | 2.42% | 0.00% |
31-Dec-2011 | 23-Feb-2012 | 31-Dec-2011 | 4 | 366,002 | 35,778 | 28,397 | 28,004 | 14,524 | 199,598 | 51.87% | 7.76% | 14.03% | 93,708 | 390.58 | 77.02 | 29.88 | 5.89 | 15.50 | 3.06 | 2.1300 | 0.42 | ![]() | ![]() | 30-Dec-2011 | 2.74 | 0.70 | 9.17 | 1.29 | 10.91% | 5.66% | 23-Feb-2012 | 2.83 | 0.72 | 9.47 | 1.33 | 10.56% | 5.48% |
31-Dec-2011 | 15-Nov-2011 | 30-Sep-2011 | 3 | 273,672 | 26,464 | 20,405 | 20,004 | 5,155 | 190,269 | 25.77% | 7.46% | 10.51% | 93,728 | 291.98 | 57.59 | 21.35 | 4.21 | 5.50 | 1.08 | 2.0300 | 0.40 | ![]() | ![]() | 30-Sep-2011 | 2.60 | 0.89 | 12.18 | 1.28 | 8.21% | 2.12% | 15-Nov-2011 | 2.84 | 0.97 | 13.31 | 1.40 | 7.51% | 1.94% |
31-Dec-2011 | 19-Aug-2011 | 30-Jun-2011 | 2 | 181,805 | 20,339 | 15,782 | 15,397 | 5,153 | 189,272 | 33.47% | 8.68% | 8.13% | 93,699 | 194.03 | 38.26 | 16.43 | 3.24 | 5.50 | 1.08 | 2.0200 | 0.40 | ![]() | ![]() | 30-Jun-2011 | 3.05 | 1.57 | 18.56 | 1.51 | 5.39% | 1.80% | 19-Aug-2011 | 2.92 | 1.50 | 17.77 | 1.45 | 5.63% | 1.88% |
31-Dec-2011 | 19-May-2011 | 31-Mar-2011 | 1 | 92,822 | 11,601 | 9,115 | 8,874 | - | 190,200 | - % | 9.82% | 4.67% | 93,694 | 99.07 | 19.53 | 9.47 | 1.87 | 0.00 | 0.00 | 2.0300 | 0.40 | ![]() | ![]() | 31-Mar-2011 | 2.90 | 2.93 | 30.62 | 1.43 | 3.27% | 0.00% | 19-May-2011 | 3.00 | 3.03 | 31.68 | 1.48 | 3.16% | 0.00% |
31-Dec-2010 | 24-Feb-2011 | 31-Dec-2010 | 4 | 313,718 | 45,094 | 38,340 | 32,941 | 12,183 | 182,745 | 36.98% | 12.22% | 18.03% | 93,715 | 334.76 | 66.01 | 35.15 | 6.93 | 13.00 | 2.56 | 1.9500 | 0.38 | ![]() | ![]() | 30-Dec-2010 | 2.59 | 0.77 | 7.37 | 1.33 | 13.57% | 5.02% | 24-Feb-2011 | 2.68 | 0.80 | 7.62 | 1.37 | 13.12% | 4.85% |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
![]() NPRA1985 Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy. ----------- US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said. Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released. The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said. Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy. But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive." https://www.globaltimes.cn/content/1206389.shtml 10/11/2020 11:54 PM NPRA1985 Sinovac vaccine is not related to any companies in Malaysia but just wanted to share anyway. ------------ Brazilian politics, US pressure likely behind Chinese vaccine's suspension: experts The Chinese Foreign Ministry, the Chinese vaccine producer and a Brazilian institute clarified that Brazilian health regulator's decision to halt trials of a Chinese-produced COVID-19 vaccine in Brazil is NOT RELATED TO THE VACCINE ITSELF, after foreign media said the suspension came following a "severe adverse event." Chinese experts said politicization of vaccine issues by some Brazilian politicians was likely the reason. They said the vaccine trial issue, which is life-saving work amid the COVID-19 pandemic, should not be influenced by Brazilian political disputes or US pressure. They stressed that the vaccine is essential to fight the virus, but the suspension without a reasonable excuse could slow down the vaccine-development process. Wang Wenbin, spokesperson of the ministry, said at a press conference on Tuesday we notice that BUTANTAN INSTITUTE, partner of China's Sinovac Biotech in Brazil, has concluded that the reported "adverse event" that caused Brazil's health regulator on Monday to suspend trials of a Chinese-produced vaccine in Brazil was NOT RELATED TO THE VACCINE produced by Sinovac. https://www.globaltimes.cn/content/1206393.shtml 11/11/2020 12:07 AM serendipity89 https://www.theedgemarkets.com/article/apex-healthcare-ready-play-role-vaccine-distribution 11/11/2020 8:48 AM JaBerry People jump to vaccine company. Do we realise without supply chain and logistics also problem? Apex play important roles and has facilities and temperature control in distributing the vaccine. 11/11/2020 9:52 AM NPRA1985 China National Pharmaceutical Group Corp (SINOPHARM), a Chinese state-owned enterprise, announced on Wednesday that data from late-stage clinical trials for its Covid-19 vaccine are «BETTER THAN EXPECTED», Reuters reported. In Morocco, Dr. Abdelhakim Yahyane, a member of the National Scientific Advisory Committee on Vaccination, told Yabiladi earier this week that vaccine trials in the country «have REACHED THE FINAL PHASE». We are impatiently awaiting the end of this process, which could probably happen BY NEXT WEEK https://en.yabiladi.com/articles/details/101544/conducted-morocco-among-others-sinopharm-s.html 13/11/2020 9:54 PM Sinoboy If moderna vaccine is for real, apex health can play a substantial role. Apparently, moderna's vaccine requires storage of only -20C. This is exactly what apex health has, storage facilities that meet this requirement. Hopefully, such important information is not lost on the public. This counter has great potential 16/11/2020 8:17 PM Russell Eventually vaccine makers will need to come to Apex Healthcare for its cold chain facility which will be completed in Q4. It just completed it’s cold chain in Singapore. Perfect stock for the recovery trend 16/11/2020 9:13 PM serendipity89 profit seems to have recovered back to pre covid level. next to see is after they completed their cold chain network, whehter they are able to secure distribution contract for the vaccine. 19/11/2020 7:46 PM Mr.Sm Invest123 Apex Pharma On 14th September, the Group’s wholly owned manufacturing subsidiary Xepa-Soul Pattinson (M) Sdn Bhd secured renewal of its GMP status with the National Pharmaceutical Regulatory Authority (‘NPRA’) through a scheduled desktop audit. In the quarter, Apex Pharma Marketing Pte Ltd in Singapore increased its cold chain distribution capabilities with the expansion of its current 2-8 degrees C cold room and the acquisition of a -20 degrees C freezer room for pharmaceuticals, vaccines and biologics. Expansion of cold chain distribution capacity in Malaysia is scheduled for completion before the end of the current financial year. Review of Year To Date Performance versus Corresponding Period Last Year 20/11/2020 12:05 AM mrmeow AHEALTH has the cold storage facility and has expanded by acquiring more cold facility and prepared for the covid19 vaccines. Don't foget this real making money one, supplying Msia and Singapore, stable & growing business even before covid, always on an uptrend 27/11/2020 9:41 AM mrmeow Everyone looking for logistics company that has cold facility for vaccine distribution, yet they forget that this pharmaceutical company does distribution too and has the logistics capable of doing the real work 27/11/2020 12:00 PM Mr.Sm Invest123 Vaccine-related: Following the approval of Budget 2021, vaccine-related companies will benefit under the Covid-19 fund/fill-and-finish process as well as distribution of vaccines once it is available in the future. Under this segment, SOLUTN, HWGB, BINTAI, DPHARMA, PHARMA, KANGER, -Ahealth, TITIJYA, MAHSING should be under traders radar. Source: M+ Online 27/11/2020 12:47 PM serendipity89 ''Apex has been approached by several manufacturers to be the authorised distributor for their upcoming Covid-19 vaccines (work-in-progress). There are many considerations in evaluating these proposals (ie. whether the products will be approved, pricings, efficiencies, requirements, etc) and hence, Apex has not committed to any manufacturer. Instead, the group will likely start off as a wholesaler, where Apex will distribute the Covid-19 vaccines from various manufacturers'' AffinHWang 28/11/2020 1:30 PM NPRA1985 PM: No call to reject 2021 Budget just to bring about polls "There is no need to do that (reject the 2021 Budget). If you ask me, I could have yesterday advised the Yang di-Pertuan Agong Al-Sultan Abdullah Ri'ayatuddin Al-Mustafa Billah Shah, to dissolve Parliament so that a general election can be held. "But we all know that the problem is Covid-19. InsyaAllah, if He allows it, when the pandemic is over, we can hold a general election. Muhyiddin added that the 2021 Budget, worth RM322.5 billion which was passed at the policy level in Parliament on Thursday, is aimed at easing the burden of the people and restoring the country's economy. "I hope the 2021 Budget will be approved at the Dewan Rakyat and subsequently at the Dewan Negara. This is to ensure that the people will receive the assistance that they need during this tough time." https://www.nst.com.my/news/politics/2020/11/645117/pm-no-call-reject-2021-budget-just-bring-about-polls 29/11/2020 9:25 PM NPRA1985 No significant change to reject budget at committee level: Dr M FORMER Prime Minister (PM) Tun Dr Mahathir Mohamad said no significant change can be achieved if the proposed Budget 2021 is rejected at the committee level debate session. “Rejecting the budget at the committee level, as it is said to be done, will not bring any significant impact on the government nor the proposed budget. “It is just an attempt to divert the criticisms of the people who are disappointed with the attitude of the Opposition,” Dr Mahathir said in a statement today. https://themalaysianreserve.com/2020/11/27/no-significant-change-to-reject-budget-at-committee-level-dr-m/ 29/11/2020 9:36 PM weijuin1992 Buy on rumours sell on fact ,it had come so far with rumours ,once confirm news will fly ,sit in if you believe in good company ! 01/12/2020 12:08 PM weijuin1992 Reversal to uptrend on small fraction of price yet big indicator to this share as it is not so volatile like the others , good chance striking up again ! 01/12/2020 5:39 PM NPRA1985 U.K. Approves Pfizer Coronavirus Vaccine, a First in the West The emergency approval, ahead of the United States and the European Union, clears the way for Britain to begin mass inoculations. “Help is on its way,” one official said. https://www.nytimes.com/2020/12/02/world/europe/pfizer-coronavirus-vaccine-approved-uk.html 02/12/2020 6:36 PM NPRA1985 Moderna Covid vaccine can get emergency authorisation approval in 2-3 days after panel meet: CEO Moderna's vaccine candidate's full results from a late-stage study showed its vaccine was 94.1% effective with no serious safety concerns https://www.livemint.com/news/world/moderna-covid-vaccine-can-get-emergency-authorisation-approval-in-2-3-days-after-panel-meet-ceo-11606922963960.html 03/12/2020 12:36 AM NPRA1985 US says Covid-19 vaccines ready to be shipped nationwide immediately https://www.freemalaysiatoday.com/category/world/2020/12/02/us-says-covid-19-vaccines-ready-to-be-shipped-nationwide-immediately/ 03/12/2020 12:37 AM NPRA1985 Janssen seeks Health Canada approval for its COVID-19 vaccine https://www.cbc.ca/news/politics/johnson-johnson-health-canada-approval-1.5823173 03/12/2020 12:37 AM NPRA1985 Johnson & Johnson has started a rolling submission with the European Medicines Agency (EMA) for its single-dose COVID-19 vaccine candidate. https://www.biopharma-reporter.com/Article/2020/12/01/Johnson-Johnson-start-rolling-review-for-COVID-19-vaccine-in-Europe 03/12/2020 12:38 AM NPRA1985 Promise of Covid vaccines is ‘phenomenal’, WHO says https://www.freemalaysiatoday.com/category/world/2020/12/03/promise-of-covid-vaccines-is-phenomenal-who-says/ 03/12/2020 10:25 PM NPRA1985 Equities up as Covid-19 cases drop, vaccine news spurs economic recovery bets https://www.theedgemarkets.com/article/fbm-klci-closes-2954-points-162826 03/12/2020 10:47 PM NPRA1985 DUBAI: Bahrain said on Friday it has granted emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, becoming the second country after Britain to approve it. The kingdom had also approved Sinopharm’s COVID-19 vaccine in November for use by frontline workers. https://www.arabnews.com/node/1772516/middle-east 05/12/2020 1:33 AM NPRA1985 South Korea reaches deal to buy AstraZeneca's Covid-19 vaccine candidate https://www.straitstimes.com/asia/east-asia/south-korea-reaches-deal-to-buy-astrazenecas-covid-19-vaccine-candidate 05/12/2020 1:46 AM NPRA1985 500 million vaccine doses in Q1 2021 closer to reality, says WHO https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/ 05/12/2020 2:34 PM NPRA1985 UAE says Sinopharm vaccine has 86% efficacy against COVID-19 DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there. The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups. The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency. “The analysis shows no serious safety concerns,” it said. It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial. https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V 09/12/2020 3:12 PM NPRA1985 United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19 TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial. The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine. The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided. The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.” The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization. https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c 09/12/2020 10:25 PM NPRA1985 Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing. “The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people. “Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed. SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there. https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/ 10/12/2020 11:55 PM NPRA1985 FDA intends to 'proceed towards an authorization' of Covid-19 vaccine, official says, as cases soar (CNN)The FDA has informed Pfizer it intends "to proceed towards an authorization" of the manufacturer's Covid-19 vaccine, the US Health and Human Services Secretary told ABC on Friday morning, as the country is deep into a worsening health crisis. The statement comes a day after an FDA panel recommended the agency grant an emergency use authorization for the Pfizer-BioNTech coronavirus vaccine.Other key steps remain, but if those hurdles are cleared, the first vaccinations in the US could happen early next week, HHS Secretary Alex Azar told ABC's George Stephanopoulos. "The FDA informed Pfizer that they do intend to proceed toward an authorization for their vaccine," Azar told ABC Friday morning. https://edition.cnn.com/2020/12/11/health/us-coronavirus-friday/index.html 12/12/2020 2:26 AM NPRA1985 Pfizer Vaccine Cleared in U.S., a Landmark in Covid-19 Fight Pfizer Inc. gained emergency U.S. authorization for its Covid-19 vaccine on Friday, completing an unprecedented scientific sprint that could eventually help bring an end to a pandemic that has killed nearly 300,000 Americans https://www.bloomberg.com/news/articles/2020-12-12/pfizer-covid-vaccine-wins-u-s-fda-emergency-use-authorization 12/12/2020 3:04 PM NPRA1985 Bursa Malaysia is expected to trend higher next week https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258 ---------------- Bursa Malaysia expected to break 1,700 psychological level Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang. https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/ 12/12/2020 6:05 PM FT1981 https://app.sinchew.com.my/content/content_2406317.html?type=detail&fileId=2406317&colID=6660 07/01/2021 11:20 AM ![]() ![]() |
|